The Neuronal Ischemic Tolerance Is Conditioned by the Tp53 Arg72Pro Polymorphism.


Journal

Translational stroke research
ISSN: 1868-601X
Titre abrégé: Transl Stroke Res
Pays: United States
ID NLM: 101517297

Informations de publication

Date de publication:
04 2019
Historique:
received: 06 02 2018
accepted: 06 04 2018
revised: 03 04 2018
pubmed: 25 4 2018
medline: 16 4 2019
entrez: 25 4 2018
Statut: ppublish

Résumé

Cerebral preconditioning (PC) confers endogenous brain protection after stroke. Ischemic stroke patients with a prior transient ischemic attack (TIA) may potentially be in a preconditioned state. Although PC has been associated with the activation of pro-survival signals, the mechanism by which preconditioning confers neuroprotection is not yet fully clarified. Recently, we have described that PC-mediated neuroprotection against ischemic insult is promoted by p53 destabilization, which is mediated by its main regulator MDM2. Moreover, we have previously described that the human Tp53 Arg72Pro single nucleotide polymorphism (SNP) controls susceptibility to ischemia-induced neuronal apoptosis and governs the functional outcome of patients after stroke. Here, we studied the contribution of the human Tp53 Arg72Pro SNP on PC-induced neuroprotection after ischemia. Our results showed that cortical neurons expressing the Pro72-p53 variant exhibited higher PC-mediated neuroprotection as compared with Arg72-p53 neurons. PC prevented ischemia-induced nuclear and cytosolic p53 stabilization in Pro72-p53 neurons. However, PC failed to prevent mitochondrial p53 stabilization, which occurs in Arg72-p53 neurons after ischemia. Furthermore, PC promoted neuroprotection against ischemia by controlling the p53/active caspase-3 pathway in Pro72-p53, but not in Arg72-p53 neurons. Finally, we found that good prognosis associated to TIA within 1 month prior to ischemic stroke was restricted to patients harboring the Pro72 allele. Our findings demonstrate that the Tp53 Arg72Pro SNP controls PC-promoted neuroprotection against a subsequent ischemic insult by modulating mitochondrial p53 stabilization and then modulates TIA-induced ischemic tolerance.

Identifiants

pubmed: 29687302
doi: 10.1007/s12975-018-0631-1
pii: 10.1007/s12975-018-0631-1
pmc: PMC6421278
doi:

Substances chimiques

Excitatory Amino Acid Agonists 0
Microtubule-Associated Proteins 0
Mtap2 protein, mouse 0
Trp53 protein, mouse 0
Tumor Suppressor Protein p53 0
N-Methylaspartate 6384-92-5
Arginine 94ZLA3W45F
Proline 9DLQ4CIU6V
Electron Transport Complex IV EC 1.9.3.1
Caspase 3 EC 3.4.22.-
Glucose IY9XDZ35W2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

204-215

Références

Brain Res Mol Brain Res. 1999 Jul 5;70(2):304-13
pubmed: 10407180
Stroke. 1999 Sep;30(9):1851-4
pubmed: 10471435
J Biol Chem. 2000 May 26;275(21):16202-12
pubmed: 10821866
Neurology. 2000 Jun 13;54(11):2089-94
pubmed: 10851368
J Neurochem. 2000 Aug;75(2):812-8
pubmed: 10899959
Neurology. 2000 Dec 12;55(11):1649-55
pubmed: 11113218
FEBS Lett. 2001 Jan 19;488(3):110-5
pubmed: 11163756
J Neurosci. 2001 Sep 1;21(17):6608-16
pubmed: 11517250
Cancer Lett. 2001 Dec 10;174(1):1-15
pubmed: 11675147
Biochem Soc Trans. 2001 Nov;29(Pt 6):684-8
pubmed: 11709054
Stroke. 2002 Jun;33(6):1698-705
pubmed: 12053014
J Neurochem. 2002 Apr;81(2):207-17
pubmed: 12064468
J Neurol. 2002 Nov;249(11):1503-11
pubmed: 12420088
Trends Neurosci. 2003 May;26(5):248-54
pubmed: 12744841
J Clin Immunol. 2003 Sep;23(5):355-61
pubmed: 14601643
Stroke. 2004 Mar;35(3):616-21
pubmed: 14963288
Nat Cell Biol. 2004 May;6(5):443-50
pubmed: 15077116
J Neurosci Res. 2004 Oct 1;78(1):132-40
pubmed: 15372497
J Mol Neurosci. 2004;24(2):299-305
pubmed: 15456943
Cell Cycle. 2004 Dec;3(12):1492-5
pubmed: 15611631
Trends Genet. 2005 Mar;21(3):182-7
pubmed: 15734577
Biochem Biophys Res Commun. 2005 Jun 10;331(3):843-50
pubmed: 15865940
J Neurosci Res. 2005 Dec 1;82(5):665-73
pubmed: 16247804
J Neurosci. 2006 Apr 26;26(17):4509-18
pubmed: 16641230
J Neurosci Res. 2006 Jul;84(1):130-41
pubmed: 16688719
Stroke. 2007 Mar;38(3):1091-6
pubmed: 17272767
EMBO J. 2008 Oct 22;27(20):2736-45
pubmed: 18818692
J Cereb Blood Flow Metab. 2009 Feb;29(2):375-84
pubmed: 18957990
Neurobiol Dis. 2009 Mar;33(3):509-17
pubmed: 19166937
Stroke. 2009 Jun;40(6):2276-93
pubmed: 19423857
Transl Stroke Res. 2010 Jan 14;1(1):4-18
pubmed: 20563278
Cancer Res. 2010 Jul 15;70(14):5851-9
pubmed: 20587514
J Exp Med. 2011 Mar 14;208(3):429-37
pubmed: 21357744
J Neurol Neurosurg Psychiatry. 2011 Sep;82(9):993-1000
pubmed: 21357987
Neurologia. 2014 Mar;29(2):102-22
pubmed: 22152803
Cell Mol Life Sci. 2013 Jan;70(1):71-88
pubmed: 22695677
Genes Cancer. 2012 Mar;3(3-4):240-8
pubmed: 23150757
Curr Opin Neurol. 2013 Feb;26(1):1-7
pubmed: 23197083
Nat Commun. 2013;4:2879
pubmed: 24301314
Prog Neurobiol. 2014 Mar;114:58-83
pubmed: 24389580
Biochim Biophys Acta. 2014 Aug;1842(8):1186-97
pubmed: 24412988
Lancet. 2014 Nov 29;384(9958):1929-35
pubmed: 25106063
Aging Dis. 2014 Feb 12;5(6):430-41
pubmed: 25489494
Cell Death Differ. 2017 Jan;24(1):144-154
pubmed: 27768124
Arch Med Sci. 2017 Aug;13(5):1057-1061
pubmed: 28883846
Sci Rep. 2018 Jan 25;8(1):1610
pubmed: 29371613
Brain Pathol. 1995 Apr;5(2):135-44
pubmed: 7670654
Stroke. 1993 Jan;24(1):35-41
pubmed: 7678184
Stroke. 1997 May;28(5):1073-80; discussion 1080-1
pubmed: 9158652
J Cereb Blood Flow Metab. 1998 Mar;18(3):238-47
pubmed: 9498840
Brain Res Brain Res Protoc. 1998 Mar;2(3):209-14
pubmed: 9507134
Stroke. 1998 Sep;29(9):1937-50; discussion 1950-1
pubmed: 9731622

Auteurs

Maria E Ramos-Araque (ME)

Institute of Biomedical Research of Salamanca, University Hospital of Salamanca, University of Salamanca, CSIC, Calle Zacarías González 2, 37007, Salamanca, Spain.
Institute of Functional Biology and Genomics, University of Salamanca, CSIC, Salamanca, Spain.

Cristina Rodriguez (C)

Institute of Biomedical Research of Salamanca, University Hospital of Salamanca, University of Salamanca, CSIC, Calle Zacarías González 2, 37007, Salamanca, Spain.
Institute of Functional Biology and Genomics, University of Salamanca, CSIC, Salamanca, Spain.

Rebeca Vecino (R)

Institute of Biomedical Research of Salamanca, University Hospital of Salamanca, University of Salamanca, CSIC, Calle Zacarías González 2, 37007, Salamanca, Spain.
Institute of Functional Biology and Genomics, University of Salamanca, CSIC, Salamanca, Spain.

Elisa Cortijo Garcia (E)

Stroke Unit, Department of Neurology, University Hospital of Valladolid, University of Valladolid, Valladolid, Spain.

Mercedes de Lera Alfonso (M)

Stroke Unit, Department of Neurology, University Hospital of Valladolid, University of Valladolid, Valladolid, Spain.

Mercedes Sanchez Barba (M)

Institute of Biomedical Research of Salamanca, University Hospital of Salamanca, University of Salamanca, CSIC, Calle Zacarías González 2, 37007, Salamanca, Spain.
Department of Statistics, University Hospital of Salamanca, University of Salamanca, Salamanca, Spain.

Laura Colàs-Campàs (L)

Clinical Neurosciences Group, IRBLleida. UdL, Lleida, Spain.

Francisco Purroy (F)

Clinical Neurosciences Group, IRBLleida. UdL, Lleida, Spain.
Stroke Unit, University Hospital Arnau de Vilanova, Lleida, Spain.

Juan F Arenillas (JF)

Stroke Unit, Department of Neurology, University Hospital of Valladolid, University of Valladolid, Valladolid, Spain.
Neurovascular Research Laboratory (i3), Instituto de Biología y Genética Molecular, Universidad de Valladolid, CSIC, Valladolid, Spain.

Angeles Almeida (A)

Institute of Biomedical Research of Salamanca, University Hospital of Salamanca, University of Salamanca, CSIC, Calle Zacarías González 2, 37007, Salamanca, Spain.
Institute of Functional Biology and Genomics, University of Salamanca, CSIC, Salamanca, Spain.

Maria Delgado-Esteban (M)

Institute of Biomedical Research of Salamanca, University Hospital of Salamanca, University of Salamanca, CSIC, Calle Zacarías González 2, 37007, Salamanca, Spain. mdesteban@usal.es.
Institute of Functional Biology and Genomics, University of Salamanca, CSIC, Salamanca, Spain. mdesteban@usal.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH